Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net revenues	$ 13,927	$ 14,812	$ 40,017	$ 42,933
Cost of products sold	6,485	5,022	14,711	13,244
Selling, general and administrative	3,372	3,304	9,679	11,843
Research and development	1,723	1,614	5,748	4,720
Acquired IPR&D and milestones	66	40	496	454
Other operating expense (income), net	0	229	(179)	57
Total operating costs and expenses	11,646	10,209	30,455	30,318
Operating earnings	2,281	4,603	9,562	12,615
Interest expense, net	398	497	1,306	1,568
Net foreign exchange loss	25	36	97	108
Other expense (income), net	(95)	(330)	3,121	427
Earnings before income tax expense	1,953	4,400	5,038	10,512
Income tax expense	172	448	989	1,139
Net earnings	1,781	3,952	4,049	9,373
Net earnings attributable to noncontrolling interest	3	3	8	10
Net earnings attributable to AbbVie Inc.	$ 1,778	$ 3,949	$ 4,041	$ 9,363
Per share data
Basic earnings per share (in dollars per share)	$ 1.00	$ 2.22	$ 2.27	$ 5.26
Diluted earnings per share (in dollars per share)	$ 1.00	$ 2.21	$ 2.26	$ 5.24
Weighted-average basic shares outstanding (in shares)	1,767	1,771	1,768	1,771
Weighted-average diluted shares outstanding (in shares)	1,771	1,776	1,772	1,777